1. Will other drugmakers end up with deals like Endo’s $10M opioid settlement? — AstraZeneca Imfinzi combo fails advanced lung cancer study — FDA says they were “lucky” with Novartis data manipulation controversy — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Neurometrix is SMOKIN HOT!!

Discussion in 'NeuroMetrix' started by Anonymous, Dec 6, 2013 at 7:57 PM.

  1. Anonymous

    Anonymous Guest

    12-5-2013 Neurometrix Inc. (NASDAQ:NURO) opened at $2.36 and after increasing by 6.65% it closed at $2.55. The stock traded in the range of $2.33 – $2.70 and its 52 week trading range is of $1.47 and $3.24. At its previous closing, the stock was down by 21.30% from its 52-week high and up by 73.47% from its 52-week low. The company traded with approximately, 0.512 million shares during the session. And its average trading volume remained 1.05 million shares. The company has market capitalization of $7.61 million with 2.99 million shares outstanding.

    The company recently announced that Shai N. Gozani who is a President and CEO of the company will speak at the 7thAnnual OneMedForum on January 13-15, 2014
     
  2. anonymous

    anonymous Guest

    What's he going to say? We are finally closing the doors? Thank god!